Ustekinumab
Ustekinumab is a pharmaceutical drug with 111 clinical trials. Currently 24 active trials ongoing. Historical success rate of 87.3%.
Success Metrics
Based on 62 completed trials
Phase Distribution
Phase Distribution
16
Early Stage
24
Mid Stage
47
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.8%
62 of 74 finished
16.2%
12 ended early
24
trials recruiting
111
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
A Long-term Extension Study of Ustekinumab in Pediatric Participants
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Clinical Trials (111)
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
A Long-term Extension Study of Ustekinumab in Pediatric Participants
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Loss of RESponse to Ustekinumab Treated by Dose Escalation
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 111